Company Description
Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China.
It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc. In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution.
Further, it operates an e-commerce platform that connects food suppliers and supermarket operators and restaurant owners.
The company was formerly known as AnPac Bio-Medical Science Co., Ltd. and changed its name to Fresh2 Group Limited in April 2023.
The company was incorporated in 2010 and is based in New York, New York.
| Country | British Virgin Islands |
| Founded | 2010 |
| IPO Date | Jan 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 75 |
Contact Details
Address: 650 Fifth Avenue, Suite 2416 New York, New York 10019-6108 United States | |
| Phone | 1 917-397-6890 |
Stock Details
| Ticker Symbol | FRES |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001786511 |
| CUSIP Number | 35803R105 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Haohan Xu | Chairman of the Board and Chief Executive Officer |
| Dr. He Yu | Co-Founder and Chief Scientist |
| Xiaoyu Li | Director and Chief Financial Officer |
| Weidong Dai | China President |
| Dr. Sunil Pandit | U.S. Chief Executive Officer |
| Yidong Hu | Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2024 | 8-K | Current Report |
| Apr 2, 2024 | 8-K | Current Report |
| Apr 2, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 27, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 20-F/A | Filing |
| Feb 16, 2024 | 8-K | Current Report |
| Feb 1, 2024 | 8-K | Current Report |
| Jan 29, 2024 | 8-K | Current Report |